

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: William F. Crismore et al.Application No./Patent No./Control No.: 10/693,305Filed/Issue Date: October 24, 2003Entitled: **ELECTROCHEMICAL BIOSENSOR TEST STRIP**Roche Diagnostics Operations, Inc.

(Name of Assignee)

Corporation

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title, and interest  
(The extent (by percentage) of its ownership interest is 50%)

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel       , Frame       , or a true copy of the original assignment is attached.

**OR**


B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet.**As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or currently is being, submitted for recordation pursuant to 37 CFR 3.11.**

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

December 21, 2007

Date

Thomas O. Henry, Reg. No. 28,309

Typed or printed name

(317) 634-3456

Telephone Number

Appointed Practitioner to Act on Behalf of Assignee  
Title

For:  U.S. and/or  Foreign Rights  
 For:  U.S. Application or  U.S. Patent  
 By: Multiple Inventors

## ASSIGNMENT OF INVENTION

For consideration.

## ASSIGNORS (inventors):

William F. Crismore Name	1215 N. Leland Avenue, Indianapolis, IN 46219 Address	U.S. Nationality
Nigel A. Surridge Name	1248 E. 90th Street, Indianapolis, IN 46240 Address	U.K. Nationality
Daniel R. McMinn Name	10517 Greenway Drive, Fishers, IN 46038 Address	U.S. Nationality
Richard J. Bodensteiner Name	5014 Central Avenue, Indianapolis, IN 46205 Address	U.S. Nationality
Eric R. Diebold Name	12580 Ensley Drive, Fishers, IN 46038 Address	U.S. Nationality
R. Dale Delk Name	1605 S. Stockport Drive, Muncie, IN 47304 Address	U.S. Nationality
David W. Burke Name	1931 Madison Court, Carmel, IN 46032 Address	U.S. Nationality
Jiaxiong Jason Ho Name	5275 Ivy Hill Drive, Carmel, IN 46033 Address	U.S. Nationality
Robert Kitchel Earl Name	12598 Spring Violet Place, Carmel, IN 46033 Address	U.S. Nationality
Brian A. Heald Name	10337 Seagrave Drive, Fishers, IN 46038 Address	U.S. Nationality

hereby sell, assign and transfer to

## ASSIGNEE:

Boehringer Mannheim Corporation Name	9115 Hague Road, Indianapolis, IN 46250 Address	U.S. Nationality
--	--	---------------------

and the successors, assigns and legal representatives of the ASSIGNEE (complete one of the following)

the entire right, title and interest  
 an undivided \_\_\_\_\_ percent (\_\_\_\_%) interest

for the United States and its territorial possessions (check the following box if foreign rights are also to be assigned)

and in all foreign countries, including all rights to claim priority  
in and to any and all improvements which are disclosed in the invention entitled:

### IMPROVED ELECTROCHEMICAL BIOSENSOR TEST STRIP

(check and complete (a), (b), (c) or (d))

and which is found in

(a)  U.S. patent application executed on even date herewith  
(b)  U.S. patent application executed on \_\_\_\_\_  
[ ] To comply with 37 CFR 3.21 for recordal of this assignment, I, an ASSIGNEE signing below, hereby authorize and request my attorney, as named in the Declaration and Power of Attorney I executed for this invention on the execution date stated above, to insert below the filing date and application number when it becomes known.  
(c)  U.S. application serial no. 08/985,840 filed on December 5, 1997.  
(d)  U.S. patent no. \_\_\_\_\_ issued \_\_\_\_\_  
[ ] A change of address to which correspondence is to be sent regarding patent maintenance fees is being sent separately.  
(CHECK (E) IF FOREIGN APPLICATION(S) IS ALSO BEING ASSIGNED)  
(e)  and any legal equivalent thereof in a foreign country, including the right to claim priority

and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof

ASSIGNEE hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNEE further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNEE and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, We have hereunto set hand and seal this \_\_\_\_\_  
(Date of signing).

WARNING: Date of signing must be the same as the date of execution of the application if item (a) was checked above.

William F. Crismore

Name

William F. Crismore 5-4-98  
Signature

5/13/98

Nigel A. Surridge

Name

Nigel A. Surridge  
Signature

5/13/98

Daniel R. McMinn

Name

Daniel R. McMinn 5/4/98  
Signature

5/4/98

Richard J. Bodensteiner

Name

Richard J. Bodensteiner 5-4-98  
Signature

5-4-98

Eric R. Diebold

Name

Eric R. Diebold 5-8-98  
Signature

5-8-98

R. Dale Delk

Name

David W. Burke

Name

Jiaxiang Jason Ho

Name

Robert Kitchel Earl

Name

Brian A. Heald

Name

R. Dale Delk

5-8-98

Signature

David W. Burke

5-6-98

Signature

Jiaxiang Jason Ho

5-1-98

Signature

Robert Kitchel Earl

5-14-98

Signature

Brian A. Heald

5/14/98

Signature

NOTE: No witnessing, notarization or legalization is necessary. If the assignment is notarized or legalized then it will only be prima facie evidence of execution 35 USC 261. Use next page if notarization is desired.

[ ] Notarization or Legalization Page Added.

198706-883

ARTICLES OF MERGER  
OF  
ROCHE DIAGNOSTIC SYSTEMS, INC. 1988110792  
INTO  
BOEHRINGER MANNHEIM CORPORATION  
(effective December 31, 1998) 198706-883

In accordance with the requirements of the Indiana Business Corporation Law, the undersigned corporations, desiring to effect a merger, set forth the following facts:

ARTICLE I - SURVIVING CORPORATION

Section 1: The name of the corporation surviving the merger is ROCHE DIAGNOSTICS CORPORATION and such name has been changed (from Boehringer Mannheim Corporation) as a result of the merger.

Section 2: The surviving corporation is a domestic corporation existing pursuant to the provisions of the Indiana Business Corporation Law, incorporated on June 25, 1987.

ARTICLE II - MERGING CORPORATION

The name, state of incorporation and date of qualification to do business in Indiana of the merging corporation is as follows:

Name:	Roche Diagnostic Systems, Inc.
State of Incorporation:	New Jersey
Date of Qualification in Indiana:	November 23, 1988

ARTICLE III - PLAN OF MERGER


The Plan of merger, containing such information as required by Section 23-1-40-1-(b) of the Indiana Business Corporation Law, is set forth on Exhibit A attached hereto and made a part hereof.

ARTICLE IV - MANNER OF ADOPTION AND VOTE

1. Action by Surviving Corporation. The outstanding capital stock of the surviving corporation consists of 1,000 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

2. Action by Merging Corporation. The outstanding capital stock of the merging corporation consists of 100 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

IN WITNESS WHEREOF, the undersigned being the President of Boehringer Mannheim Corporation, executes these Articles of Merger and verifies, subject to penalties of perjury, that the statements contained herein are true this 11th day of December, 1998.



Dennett O. Ware  
President

**AGREEMENT AND PLAN OF MERGER  
 OF  
 ROCHE DIAGNOSTIC SYSTEMS, INC.  
 INTO  
 BOEHRINGER MANNHEIM CORPORATION**

**AGREEMENT AND PLAN OF MERGER** dated December 11, 1998 between  
 Boehringer Mannheim Corporation, an Indiana corporation ("BMC"), and Roche Diagnostic  
 Systems, Inc., a New Jersey corporation ("RDS").

**WITNESSETH:**

**WHEREAS**, BMC is a corporation duly organized and existing under the laws of the  
 State of Indiana; and

**WHEREAS**, RDS is a corporation duly organized and existing under the laws of the  
 State of New Jersey; and

**WHEREAS**, the Boards of Directors of both BMC and RDS deem it advisable and in the  
 best interests of their respective corporations that RDS be merged with and into BMC; now,  
 therefore, it is agreed that

1. At the Effective Time (as that term is hereinafter defined), and upon the terms and  
 conditions set forth in Section 3 below, RDS shall be merged with and into BMC, with BMC as  
 the surviving corporation in such merger (the "Surviving Corporation").

2. As to each constituent corporation, the designation and number of outstanding  
 shares of each class and series and the voting rights thereof are as follows:

<u>Corporation</u>	<u>Designation and number of shares in each class or series outstanding</u>	<u>Shares entitled to vote</u>
RDS	Common Stock, 100 shares \$1.00 par value	100 shares
BMC	Common Stock, 1,000 shares, no par value	1,000 shares

3. The terms and conditions of the merger are as follows:

A. Share Cancellation. In view of the fact that a single shareholder owns all of the  
 issued and outstanding capital stock of BMC and RDS, at the Effective Time each share of the  
 Common Stock, par value \$1.00 per share, of RDS issued and outstanding immediately prior to

the Effective Time shall be automatically canceled and certificates for such shares shall be surrendered and canceled.

B. **Articles of Incorporation and By-Laws.** The Articles of Incorporation and By-Laws of BMC shall continue as the Articles of Incorporation and By-Laws of the Surviving Corporation; provided, however, that Article I of the Articles of Incorporation shall be amended to read; "The name of the Corporation is Roche Diagnostics Corporation."

C. **Shares of Surviving Corporation.** Each share of the Common Stock, no par value, of BMC issued and outstanding immediately prior to the Effective Time shall continue unchanged as one share of the stock of the Surviving Corporation, without the issuance or exchange of new shares or share certificates.

D. **Assets; Liabilities.** At the Effective Time, all the property, real and personal, rights, privileges, immunities, powers, purposes, franchises, patents, licenses, trademarks, registrations, causes of action, and every other asset of BMC and RDS shall be transferred to, vest in and devolve upon the Surviving Corporation, without further act or deed, and every interest of BMC and RDS shall be as effectively the property of the Surviving Corporation as they were of BMC and RDS, respectively. The Surviving Corporation shall assume and be liable for all liabilities, obligations, and penalties of BMC and RDS.

E. **Directors and Officers.** The directors and officers of the Surviving Corporation shall continue unchanged at and after the Effective Time.

F. **Abandonment.** Notwithstanding the approval and adoption of this Plan and Agreement of Merger by the sole stockholder of either or both BMC and RDS, this Agreement of Merger may be terminated at any time prior to the Effective Time by the Board of Directors of either BMC or RDS.

4. **Effective Time.** The merger of RDS into BMC shall be effective on December 31, 1998, and for accounting purposes shall be deemed to have occurred as of 11:59 p.m. on such date (the "Effective Time").

IN WITNESS WHEREOF, the undersigned have signed this Agreement as of the date first above written.

BOEHRINGER MANNHEIM CORPORATION

By: /s/ Dennert O. Ware  
Name: Dennert O. Ware  
Title: President

ROCHE DIAGNOSTIC SYSTEMS, INC.

By: /s/ Vincent P. Mihalik  
Name: Vincent P. Mihalik  
Title: Executive Vice President

**ASSET CONVEYANCE, GENERAL ASSIGNMENT  
AND ASSUMPTION AGREEMENT**

This Asset Conveyance, General Assignment and Assumption Agreement (the "Agreement") effective as of January 1, 2004, is between Roche Diagnostics Corporation, an Indiana corporation ("RDC") and Roche Diagnostics Operations, Inc., a Delaware corporation ("RDOI"). RDC and RDOI are referenced individually as "Party" and collectively as "Parties".

**WHEREAS**, RDC deems it desirable to transfer certain assets and operations to its subsidiary RDOI for the purpose of aligning RDC's legal entity structure with local and global structure and accountabilities.

**WHEREAS**, this Agreement is necessary to evidence certain contributions to the capital of RDOI by RDC and to evidence the assumption of certain liabilities and obligations by RDOI.

**WHEREAS**, it is intended by the Parties that the exchange contemplated herein qualify for tax-free treatment under Section 351 of the Internal Revenue Code of 1986, as amended.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, RDC hereby assigns, transfers, conveys and delivers to RDOI free and clear of all liens (except as otherwise provided in Exhibit A), the following assets constituting personal property relating to or associated with the business to be conducted by RDOI:

- (a) Intangible Property. RDC's right, title and interest in and to all patents, patent applications, trademarks, and trademark applications listed on Exhibit B and all license agreements recited in Exhibit B to the extent those license agreements allow assignment from RDC to RDOI (the "Transferred Intellectual Property");
- (b) Transferred Contracts. RDC's right, title and interest in and to the contracts listed in Exhibit C to the extent those contracts may be assigned from RDC to RDOI (the "Transferred Contracts");
- (c) Tangible Personal Property Owned by RDC. RDC's right, title and interest in and to all tangible personal property listed in Exhibit D (the "Transferred Personal Property"); and
- (d) Tangible Personal Property Rented or Leased by RDC. RDC's leasehold interests and rights in and to the tangible personal property located in the Leased Premises and currently being leased or rented by RDC from a third party pursuant to the lease or rental agreements listed in Exhibit E (the "Personal Property Leases").

RDOI hereby assumes and agrees to perform RDC's obligations under the Transferred Contracts. RDC hereby assigns and conveys to RDOI any and all rights it may have to receive payments, revenues, or other receipts under the Transferred Contracts for work performed or services or materials provided under the Transferred Contracts after the date hereof and relinquishes any and all rights it may have to such payments, revenues, and receipts.

RDOI hereby assumes and agrees to perform RDC's obligations under the Personal Property Leases to the extent that the Personal Property Leases cover tangible personal property located in the Leased Premises. RDOI agrees to pay RDC RDOI's pro rata share of any and all payments due from RDC to a third party with respect to tangible personal property located in the Leased Premises.

RDC agrees that from time to time, whether on or after the date hereof, it will execute and deliver such other documents and take such other actions as may reasonably be required to transfer, assign and convey to RDOI more effectively the assets which are the subject of this Agreement.

This Agreement shall inure to the benefit of and shall be binding upon the parties, their successors and assigns.

This Agreement may be executed in separate counterparts, each of which when so executed shall be an original, but all of such counterparts shall constitute but one and the same instrument.

IN WITNESS WHEREOF, RDC and RDOI have executed this Asset Conveyance, General Assignment and Assumption Agreement as of the date first written above.

ROCHE DIAGNOSTICS CORPORATION

By: M. Madans

Printed: MARTIN MADANS

Title: President - CEO



ROCHE DIAGNOSTICS OPERATIONS, INC.

By: NJC

Printed: Ned J Campbell

Title: President



## ADDENDUM

This is an Addendum to subparagraph (a) Intangible Property of the "Asset Conveyance, General Assignment and Assumption Agreement", attached hereto:

"RDC's right, title and interest in any and all applications arising from the patents, patent applications listed in Exhibit B, including any and all divisionals, continuations, continuations-in-part thereof, and any and all patents to be issued and obtained therefor and thereon, United States and foreign, including all reissues and extensions thereof."

IN WITNESS WHEREOF, RDC and RDOI have agreed that this Addendum to the "Asset Conveyance, General Assignment and Assumption Agreement" is effective as of January 1, 2004.

ROCHE DIAGNOSTICS CORPORATION (RDC)

By: Lynn M. Gagel

Printed: Lynn M. Gagel

Title: Assistant Secretary



Law Doc. I  
Approved  
As To Form

ROCHE DIAGNOSTICS OPERATIONS, INC.  
(RDOI)

By: Steve A. Oldham

Printed: Steve A. Oldham

Title: Vice President, General Counsel and Secretary



Law Doc. I  
Approved  
As To Form

**RDC PENDING REPORT**

Case	Title	Country	Appln. No.	Appln. Date	Grant No.	Grant Date	Holder	Atty
19142 EP	Capillary hemocrit separation structure and method	EP	00123020.0	10/24/2000 0:00			ROCHE RDC INDI	SS
19137 EP	Embedded metallic deposits forming an electrode set for an e	EP	00123693.4	10/31/2000 0:00			ROCHE RDC INDI	SS
19083 EP	BIOSENSOR APPARATUS	EP	00127129.5	12/12/2000 0:00			ROCHE RDC INDI	SS
19083 EP1	Biosensor or	EP	00127129.5-2204	11/22/2000 0:00			ROCHE RDC INDI	SS
19147 EP	Thermally conductive sensor	EP	00127765.6	12/19/2000 0:00			ROCHE RDC INDI	SS
19146 EP	Microsphere containing sensor	EP	00127769.8	12/19/2000 0:00			ROCHE RDC INDI	SS
19148 EP	Cell for electrochemical analysis of a sample and method	EP	00127858.9	12/20/2000 0:00			ROCHE RDC INDI	SS
19149 EP	Cell for electrochemical analysis of a sample and method	EP	00127859.7	12/20/2000 0:00			ROCHE RDC INDI	SS
19091 EP	Hospital meter system	EP	00912044.5	8/21/2001 0:00			ROCHE RDC INDI	SS
19084 EP	ENZYMATIC MEASUREMENT OF MYCOPHENOLIC ACID	EP	00935908.4	5/1/2000 0:00			ROCHE RDC INDI	AM
19084 EP1	Enzymatic measurement of mycophenolic acid	EP	00935908.4-2116	12/31/2001 0:00			ROCHE RDC INDI	AM
19096 EP	Enzyme inhibition immunoassay	EP	00941723.9	2/12/2001 0:00			ROCHE RDC INDI	AM
19140 EP	METHOD, REAGENT AND TEST CARTRIDGE	EP	00957770.1	8/24/2000 0:00			ROCHE RDC INDI	HB
19082 EP	Electrochemical sensor and method for continuous analyte mon	EP	00985134.0	2/27/2002 0:00			ROCHE RDC INDI	SS
19085 EP	Laser defined features for patterned laminates and electrode	EP	00987259.3	3/1/2002 0:00			ROCHE RDC INDI	SS
19268 EP	Amperometric biosensor test strip	EP	00989267.0	5/17/2002 0:00			ROCHE RDC INDI	SS
22170 JP	Capillary stop-flow junction having improved stability again	JP	04-44588	3/2/1992 0:00			ROCHE RDC INDI	HB
18382 JP	Extender containing polymer compositions and uses thereof	JP	06-524393	4/21/1994 0:00			ROCHE RDC INDI	YM
22156 US1	Blood Separation Device under low pressure conditions	US	071163392	3/21/1988 0:00			ROCHE RDC INDI	HB
19134 US1	Nucleic Acid Assay Method	US	071483909	2/22/1990 0:00			ROCHE RDC INDI	HB
19130 US	Fluorescence Assay Apparatus	US	071612869	11/13/1990 0:00			ROCHE RDC INDI	HB
19076 US	CAPILLARY MIXING DEVICE	US	071867155	4/10/1992 0:00			ROCHE RDC INDI	HB
22113 US	Method and apparatus for measuring specific binding assays	US	071980497	1/12/23/1992 0:00			ROCHE RDC INDI	HB
18711 US	NIR CALIBRATION	US	08001950	8/7/1995 0:00			ROCHE RDC INDI	HB
19053 US	INSTRUMENT SETUP UTILITY PROGRAM	US	08067499	12/4/1997 0:00			ROCHE RDC INDI	HB
19130 US1	Fluorescence assay apparatus	US	081350869	12/7/1994 0:00			ROCHE RDC INDI	HB
22185 US	Immunoassay System	US	081398717	8/25/1998 0:00			ROCHE RDC INDI	HB
18662 FFR	Evanescent wave immunoassay system	FR	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 DE	Evanescent wave immunoassay system	DE	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 ES	Evanescent wave immunoassay system	ES	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 GB	Evanescent wave immunoassay system	GB	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 IT	Evanescent wave immunoassay system	IT	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 JP	Evanescent wave immunoassay system	JP	08-528391	1/25/1996 0:00			ROCHE RDC INDI	HB
19163 US3	Liquid reagent set for L-lactate determination	US	09/006212	1/31/2002 0:00			ROCHE RDC INDI	AM

18210	US2	Reagent and assay methods including a phenazine-containing i	US	08/598181-	2/7/1996 0:00	5707820	1/13/1998 0:00	ROCHE RDC INDI	YM
18436	US4	Fluid dose, flow and coagulation sensor for medical instrument	US	08/478409	6/7/1995 0:00	5710622	1/20/1998 0:00	ROCHE RDC INDI	HB
19136	US2	Multiplex immunoassay System	US	08/222113	4/4/1994 0:00	5719063	2/17/1998 0:00	ROCHE RDC INDI	HB
19001	FR	CRADLE FOR INSTRUMENT	FR	995192	8/18/1999 0:00	572,209-57	2/18/2000 0:00	ROCHE RDC INDI	
18523	US1	Method and apparatus for automatic control of instruments th	US	08/423816	4/18/1995 0:00	5724066	3/3/1998 0:00	ROCHE RDC INDI	AM
18557	US2	Purified mixture of collagenase I, collagenase II, and two o	US	08/590957-	1/24/1996 0:00	5753485	5/19/1998 0:00	ROCHE RDC INDI	WK
18667	US	Electrochemical biosensor test strip	US	08/496939	6/30/1995 0:00	5762770	6/19/1998 0:00	ROCHE RDC INDI	YM
18732	US1	Apparatus and method for conducting a binding assay on an ab	US	08/877189	6/17/1997 0:00	5770458	6/23/1998 0:00	ROCHE RDC INDI	HB
18436	US1	Fluid dose, flow and coagulation sensor for medical instrument	US	08/623872	3/29/1996 0:00	5789664	8/4/1998 0:00	ROCHE RDC INDI	HB
18437	US1	Power supply monitor and control for medical instrument	US	08/697019	8/16/1996 0:00	5792944	8/11/1998 0:00	ROCHE RDC INDI	AM
22129	US	Stable aqueous reagent containing NAD	US	08/791920	1/31/1997 0:00	5804403	9/8/1998 0:00	ROCHE RDC INDI	WK
18313	US	Assay using an unblocked solid phase with immobilized analyt	US	07/943897	9/1/1992 0:00	5807752	9/15/1998 0:00	ROCHE RDC INDI	HB
18312	US	Casing means for analytical test apparatus	US	07/940916	9/3/1992 0:00	5820826	10/13/1998 0:00	ROCHE RDC INDI	HB
18742	US	Enzyme composition for tissue dissociation	US	08/7760893	12/6/1996 0:00	5830741	1/13/1998 0:00	ROCHE RDC INDI	WK
18435	US1	Analog heater control for medical instrument	US	08/554755	1/17/1995 0:00	5832921	1/10/1998 0:00	ROCHE RDC INDI	HB
18423	US	Magnet for medical instrument	US	08/114896	8/31/1993 0:00	5841023	1/12/1998 0:00	ROCHE RDC INDI	YM
18641	US1	Reagent including an osmium-containing redox mediator	US	08/770975	12/20/1996 0:00	5846702	12/8/1998 0:00	ROCHE RDC INDI	HB
21220	US1	Synchronized test system	US	08/908866	10/30/1997 0:00	5872713	2/16/1999 0:00	ROCHE RDC INDI	SS
21197	US1	Methods for applying a reagent to an analytical test device	US	09/004604	1/8/1998 0:00	5878957	3/2/1999 0:00	ROCHE RDC INDI	SS
21204	US1	Blood fluid sampling device and methods of use	US	08/857680	5/16/1997 0:00	5879311	3/9/1999 0:00	ROCHE RDC INDI	SS
21203	US4	Diagnostic compositions and devices utilizing same	US	09/037653	3/10/1998 0:00	5885790	3/23/1999 0:00	ROCHE RDC INDI	SS
18437	US2	Power supply monitor and control for medical instrument	US	08/983672	10/31/1997 0:00	5888252	3/23/1999 0:00	ROCHE RDC INDI	HB
19289	US	Detection of low level hydrophobic analytes in environmental	US	08/832168	4/2/1997 0:00	5891740	4/6/1999 0:00	ROCHE RDC INDI	HB
18388	US1	PROBENSAMMELUMSCHLAG	US	08/757374	1/12/1997 0:00	5895704	4/20/1999 0:00	ROCHE RDC INDI	YM
19078	US	Method of detecting organisms in a sample	US	08/957676	1/12/1997 0:00	5902722	5/1/1999 0:00	ROCHE RDC INDI	AM
18906	US	Diazonium assay reagents and methods for their use	US	08/032158	2/27/1998 0:00	5935661	8/10/1999 0:00	ROCHE RDC INDI	AM
18965	US	Phencyclidine analogs for immunoassay	US	08/831206	4/12/1997 0:00	5939332	8/17/1999 0:00	ROCHE RDC INDI	HB
19288	US	Detection of low level analytes in samples using agglutinat	US	09/184616	1/12/1998 0:00	5942442	8/24/1999 0:00	ROCHE RDC INDI	WK
18742	US1	Enzyme composition for tissue dissociation	US	08/823111	3/24/1997 0:00	5952215	9/4/1999 0:00	ROCHE RDC INDI	WK
18911	US	Procedure for subtractive hybridization and difference analy	US	08/961942	10/31/1997 0:00	5958738	9/28/1999 0:00	ROCHE RDC INDI	WK
21198	US1	Opaque reaction matrix for analysis of whole blood	US	09/029671	2/13/1998 0:00	5968765	10/19/1999 0:00	ROCHE RDC INDI	SS
19072	US	Capillary fill test device with improved fluid delivery	US	08/663922	6/14/1996 0:00	5981199	11/9/1999 0:00	ROCHE RDC INDI	HB
18733	US	Method for measuring antigen concentration	AU	08/439187	10/28/1997 0:00	598312	11/6/1999 0:00	ROCHE RDC INDI	SS
22156	AU	Blood separation device under low pressure conditions	US	08/938840	12/5/1997 0:00	6997817	12/7/1999 0:00	ROCHE RDC INDI	SS
19032	US	Electrochemical biosensor test strip	US	09/164405	9/30/1998 0:00	6001239	12/14/1999 0:00	ROCHE RDC INDI	HB
21211	US1	Membrane based on electrochemical test device and related me	US	08/406380	3/17/1995 0:00	6008057	12/28/1999 0:00	ROCHE RDC INDI	
22185	US1	Immunoassay system	US						

**RDC GRANTED REPORT**

Case	Title	Country	Appln. No.	Appln. Date	Grant No.	Grant Date	Holder	Attv
19127 FR1	Coagulation Characteristic Testing Instrument	FR	0295	4/28/1994 0:00	0295	9/30/1994 0:00	ROCHE RDC INDI	HB
19129 IT	Accessory box for cradle for instrument (Design)	IT	TO980000246	8/31/1999 0:00	00075742	3/14/2002 0:00	ROCHE RDC INDI	SS
19126 FR	Coagulation characteristic testing instrument (Design)	FR	002033	3/30/2000 0:00	002033	4/27/1994 0:00	ROCHE RDC INDI	HB
22181 FR	Assay Apparatus and Method	FR	84303759.9	6/5/1984 0:00	0128723	1/11/1993 0:00	ROCHE RDC INDI	HB
22181 GB	Assay Apparatus and Method	GB	84303759.9	6/5/1984 0:00	0128723	1/11/1993 0:00	ROCHE RDC INDI	HB
19001 ES	Cradle for instrument (Design)	ES	146290	9/1/1999 0:00	0146290	7/7/2000 0:00	ROCHE RDC INDI	SS
22153 CH	Capillary Flow Device	CH	0212314	7/24/1986 0:00	0212314	4/27/1994 0:00	ROCHE RDC INDI	HB
22153 GB	Capillary flow device	GB	0212314	7/24/1986 0:00	0212314	4/27/1994 0:00	ROCHE RDC INDI	HB
22153 IT	Capillary flow device	IT	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 AT	Integrated drug dosage form and metering system	AT	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 BE	Integrated drug dosage form and metering system	BE	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 CH	Integrated drug dosage form and metering system	CH	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 FR	Integrated drug dosage form and metering system	FR	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 GB	Integrated drug dosage form and metering system	GB	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 IT	Integrated drug dosage form and metering system	IT	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 LU	Integrated drug dosage form and metering system	LU	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 NL	Integrated drug dosage form and metering system	NL	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22113 DE	Method and apparatus for measuring specific binding assays	DE	86905538.4	8/21/1986 0:00	0233939	1/1/13/1991 0:00	ROCHE RDC INDI	HB
22113 FR	Method and apparatus for measuring specific binding assays	FR	86905538.4	8/21/1986 0:00	0233939	1/1/13/1991 0:00	ROCHE RDC INDI	HB
22113 GB	Method and apparatus for measuring specific binding assays	GB	86905538.4	8/21/1986 0:00	0233939	1/1/13/1991 0:00	ROCHE RDC INDI	HB
22113 IT	Method and apparatus for measuring specific binding assays	IT	86905538.4	8/21/1986 0:00	0233939	1/1/13/1991 0:00	ROCHE RDC INDI	HB
22156 BE	Blood separation device under low pressure conditions	BE	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 CH	Blood separation device under low pressure conditions	CH	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 FR	Blood separation device under low pressure conditions	FR	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 GB	Blood separation device under low pressure conditions	GB	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 IT	Blood separation device under low pressure conditions	IT	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 LU	Blood separation device under low pressure conditions	LU	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 NL	Blood separation device under low pressure conditions	NL	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22140 NL	Test piece coloration comparative decision unit (EVR III)	NL	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 FR	Test piece coloration comparative decision unit (EVR III)	FR	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 IT	Test piece coloration comparative decision unit (EVR III)	IT	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 GB	Test piece coloration comparative decision unit (EVR III)	GB	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22160 CH	Apparatus and Method for Delution and mixing of Liquid	CH	0305210	8/26/1988 0:00	0305210	12/8/1993 0:00	ROCHE RDC INDI	HB
22160 FR	Apparatus and Method for Delution and mixing of Liquid	FR	0305210	8/26/1988 0:00	0305210	12/8/1993 0:00	ROCHE RDC INDI	HB